A category of products has grown quickly over the past several years by occupying a genuine gap in federal law, compounds that don't naturally exist in significant quantities in the raw plant, or that come from an entirely different plant altogether, but that are chemically converted or concentrated into something intoxicating and sold through retail channels that never required a cannabis dispensary license. 7-OH and semi-synthetic cannabinoids like HHC, THC-O, and Delta-8 are the most prominent examples, and both categories are facing major regulatory upheaval as of this writing. Here's what these products actually are, and what's genuinely changing.
7-hydroxymitragynine, commonly shortened to 7-OH, is a compound related to kratom rather than cannabis, it's a metabolite of mitragynine, kratom's primary active compound, and occurs only in small natural amounts in the raw kratom leaf. Commercial 7-OH products, sold as tablets, gummies, and dissolvable strips, are typically concentrated or synthetically enhanced well beyond what raw kratom leaf naturally contains, producing a considerably more potent, opioid-like effect than traditional kratom leaf products. Our guide on 7-OH tablet dosage and effects covers the tablet format specifically in more depth.
This is genuinely a different substance category from cannabis entirely, but it's included here because it's frequently sold alongside hemp-derived cannabinoid products in the same smoke shops and online retailers, and it's undergoing regulatory action at the same time, which has caused understandable confusion about how the two relate.
In July, the DEA announced its intent to temporarily place concentrated 7-OH, above a specific threshold, along with several related synthetic derivatives not found in nature, into Schedule I of the Controlled Substances Act. This action specifically targets concentrated and synthetic 7-OH products, explicitly excluding natural kratom leaf below the proposed threshold. As of this writing, the temporary scheduling order has not yet been formally published, meaning 7-OH itself remains federally uncontrolled for now, though the regulatory action is actively in progress and could take effect on short notice. Several states have already independently restricted or banned concentrated 7-OH products ahead of any federal action.
Unlike 7-OH, semi-synthetic cannabinoids are directly cannabis-related, but they're produced through a chemical conversion process rather than extracted directly from the plant in meaningful natural quantities. HHC (hexahydrocannabinol), THC-O (a modified acetate form of THC), and Delta-8 THC are typically synthesized starting from hemp-derived CBD, using a chemical conversion process to produce an intoxicating compound that technically wasn't extracted as marijuana, since it began as legal hemp-derived CBD.
This conversion process is exactly the loophole that's about to close. These compounds have existed in federal legal gray areas since 2019, marketed as legal alternatives to traditional THC precisely because the 2018 Farm Bill's hemp definition didn't clearly address chemically converted cannabinoids.
This is the single most consequential regulatory shift affecting this entire product category, and it's worth understanding clearly. Legislation passed in late 2025 rewrites the federal definition of hemp in three major ways, phasing in over November and December 2026:
- Synthetic and chemically converted cannabinoids are excluded from the hemp definition entirely, regardless of dose. This directly eliminates HHC, THC-O, and similar lab-converted compounds from legal hemp status starting in mid-November 2026.
- The hemp definition shifts to a total THC standard that includes THCA and other THC isomers, not just Delta-9 THC. This closes the THCA flower loophole that allowed high-potency, low-Delta-9 flower to be sold as hemp.
- Finished consumer products are capped at a very low total THC amount per container, a limit so far below typical current product doses that most existing hemp-derived gummies, beverages, and vapes on the market today would no longer qualify as legal hemp once this standard takes effect.
The practical effect, according to industry estimates, is that a large majority of currently available hemp-derived intoxicating products, HHC, Delta-8, high-THCA hemp flower, and hemp-derived THC beverages and edibles marketed outside the licensed cannabis dispensary system, would become federally unlawful once these changes take full effect. There has been active legislative back-and-forth over the exact implementation dates and whether some provisions might be delayed or modified, so the precise timeline should be confirmed against current official sources rather than treated as fixed.
| Product Category |
Affected by the Hemp Law Change |
| HHC, THC-O, and other lab-converted cannabinoids |
Yes, excluded from hemp status regardless of dose |
| High-THCA hemp flower sold outside licensed dispensaries |
Yes, once total THC (including THCA) becomes the legal standard |
| Hemp-derived THC beverages and edibles sold at typical doses |
Yes, due to the new low per-container THC cap |
| Cannabis sold through state-licensed dispensaries |
No, this is regulated under separate state cannabis law, not the federal hemp definition |
| Non-intoxicating, low-THC CBD wellness products |
Potentially affected if trace THC content exceeds the new container cap, an area of active legislative concern |
If you primarily buy cannabis through a state-licensed dispensary rather than a gas station, smoke shop, or online hemp retailer, this regulatory shift affects you less directly, since dispensary cannabis operates under state cannabis licensing rather than the federal hemp definition. That said, it's still worth understanding, since some dispensaries also carry hemp-derived products, and the broader disruption to the unregulated hemp market may shift more consumers toward licensed dispensaries for products, like high-THCA flower or minor cannabinoid options, that were previously available through less-regulated hemp channels.
- Check the specific product type you use against the categories above to understand whether it's likely to be affected by the hemp law changes or the separate 7-OH action.
- Follow official sources for exact effective dates, since the implementation timeline has been subject to legislative adjustment and delay proposals, checking current federal and state-specific updates is more reliable than relying on a single fixed date.
- Consider whether a licensed dispensary carries a comparable, more clearly regulated alternative, since state-licensed cannabis products aren't subject to the same federal hemp definition changes and generally carry more consistent lab testing requirements already.
- If you use 7-OH specifically, be aware this involves a genuinely different substance with a different risk profile than cannabis-related products, and dependence and withdrawal concerns tied to its opioid-receptor activity are worth taking seriously regardless of the regulatory outcome.
Both of these regulatory threads point in the same general direction: federal and state regulators are closing gaps that allowed intoxicating products to be sold with far less oversight than licensed cannabis dispensaries operate under. Whatever the exact final timeline turns out to be, the direction is clear enough that products relying on the hemp-derived semi-synthetic loophole, or on concentrated 7-OH sold outside any cannabis regulatory framework at all, face a shrinking window of availability in their current form.
Frequently asked questions
No, 7-OH comes from kratom, a plant unrelated to cannabis, while HHC and Delta-8 are cannabinoids chemically converted from hemp-derived CBD. They're different substances undergoing separate, unrelated regulatory actions that happen to be occurring around the same time.
Based on the federal hemp law changes set to take effect in late 2026, products relying on chemical conversion from hemp-derived CBD are set to lose their legal hemp status regardless of dose. Some products may still be available through state-licensed cannabis dispensaries, where allowed under state law, since that market operates under separate marijuana regulations rather than the federal hemp definition.
If it's sold through a state-licensed cannabis dispensary, it's likely regulated under your state's marijuana laws rather than the federal hemp definition, so the change matters less directly. If it's THCA flower sold through a non-dispensary hemp retail channel relying on the low-Delta-9, high-THCA loophole, that specific sales channel is more directly affected by the total-THC standard change.
As of this writing, concentrated 7-OH remains federally uncontrolled while the DEA's temporary scheduling process is still underway, though several states have already independently restricted or banned it. Checking your specific state's current status is necessary, since state law may already be more restrictive than federal law at this point.
The 2018 Farm Bill's hemp definition focused specifically on Delta-9 THC content to distinguish industrial hemp from marijuana, without anticipating that manufacturers would use chemical conversion processes to create other intoxicating cannabinoids from otherwise-compliant hemp-derived CBD. The upcoming law changes are largely a direct legislative response to that unintended gap.
Federal treatment of previously purchased products after a law's effective date is a genuinely unsettled legal question, and enforcement priorities typically focus on manufacturing and sale rather than personal possession of previously bought items. This is an evolving area, so checking current guidance if you have specific concerns is a reasonable precaution.
This article was reviewed by the Dispensary Click Editorial Team for accuracy, clarity, and relevance. Information may be sourced from publicly available cannabis resources, state regulatory agencies, and lab-testing references where applicable.
Last reviewed: September 2026
Related articles
Buying Guides
